Subsequently, the most promising epitopes were combined to obtain signature-specific ROC curves, as described in the Methods section, both for the TPS (tumor presence signature: CD2, CD3, CD56, CD146) and the NIS (Nodal Involvement Signature: CD24, CD31, CD40) showing combined AUCs which are higher compared to the single epitopes’ AUC. This evidence concerns the gene CD2 and neoplasm.